The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients
Primary Purpose
Liver Cancer
Status
Recruiting
Phase
Not Applicable
Locations
Hong Kong
Study Type
Interventional
Intervention
Fast-track peri-operative program
Sponsored by
About this trial
This is an interventional supportive care trial for Liver Cancer focused on measuring Liver, Digestive system
Eligibility Criteria
Inclusion Criteria:
- All consecutive patients undergoing elective liver resection (open and laparoscopic).
- Age of patients between 18 and 70 years.
- Patients with American Society of Anaesthesiologists (ASA) grading I-II.
- Patients with no severe physical disability.
- Patients who require no assistance on the activities of daily living.
- Informed consent available will be recruited.
Exclusion Criteria:
- Patients undergoing emergency surgery.
- Patients who had received pre-operative portal vein embolization.
- Patients who are expected to receive concomitant procedures other than cholecystectomy.
- Pregnant ladies and patients who are mentally incapable of written consent will be excluded.
- Patient who had previous history of Hepato-biliary and pancreatic surgery.
- Patient who had chronic pain syndrome.
Sites / Locations
- Department of SurgeryRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Fast-track Arm
Conventional Group
Arm Description
Patients recruited will undergo ERAS perioperative program.
Patients recruited to conventional group will undergo conventional perioperative program
Outcomes
Primary Outcome Measures
Length of post-operative hospital Stay
Post-operative hospital stay.
Secondary Outcome Measures
Full Information
NCT ID
NCT03223818
First Posted
November 11, 2015
Last Updated
April 10, 2022
Sponsor
Chinese University of Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT03223818
Brief Title
The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients
Official Title
The Impact of Fast-track Perioperative Program on the Clinical and Immunological Outcomes After Liver Resection in Hong Kong Chinese Patients: A Prospective Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
July 1, 2023 (Anticipated)
Study Completion Date
July 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Liver cancer was the third leading cause of cancer death in both sexes in Hong Kong and liver resection remains the mainstay of curative treatment. Post-operative recovery from liver resection has historically been fraught with a high incidence of complications, ranging from 15-48%, and the high incidence of complications leads to prolonged hospital stay, ranging from 9 - 15 days, and increase costs of hospitalization. Recent advancement in the perioperative surgical and anesthetic management of patients undergoing liver resection has led to improvement in these outcomes.
The investigators department had previously studied the impact and confirmed the benefit of fast-track peri-operative programs after laparoscopic colorectal surgery. Nevertheless, studies regarding its adoption in liver resection are limited. The investigators group had previously reported, in a retrospective cohort, that successful implementation of ERAS protocol was associated with a significantly shorten hospital stay. However, the peri-operative management in that study incorporated a small proportion of components described in ERAS programs for liver resection and there was no direct comparison with conventional peri-operative program.
The aim of this study is to compare the clinical and immunological outcomes of Hong Kong Chinese patients undergoing liver resection for liver cancer with a "conventional" vs a "fast-track" perioperative program.
Detailed Description
Liver cancer was the third leading cause of cancer death in both sexes in Hong Kong and liver resection remains the mainstay of curative treatment. Post-operative recovery from liver resection has historically been fraught with a high incidence of complications, ranging from 15-48%, and the high incidence of complications leads to prolonged hospital stay, ranging from 9 - 15 days, and increase costs of hospitalization. Recent advancement in the perioperative surgical and anesthetic management of patients undergoing liver resection has led to improvement in these outcomes.
Since its formal introduction in 1990s, fast-track or enhanced recovery after surgery (ERAS) peri-operative programs have gained territory quickly because of the associated cost efficiency derived from the reduction in hospital stay, an important issue in today's context of rapidly increasing health care costs and the consequent need for optimization. The benefits of fast-track peri-operative programs have been well proven in colectomy. Our department had previously demonstrated the feasibility and impact of fast-track peri-operative programs after laparoscopic colorectal surgery, which leads to the potential for application to other subspecialties. Nevertheless, studies evaluating fast-track peri-operative programs in liver resection are scarce. Most of them were carried out in Western countries and almost all of them used epidural analgesia for post-operative pain control. While most of the livers in Western patients are non-cirrhotic, the main challenge of liver resection in Chinese Hong Kong patients is the background liver cirrhosis as hepatitis-related hepatocellular carcinoma is the most common indication for liver resection. Although epidural analgesia has been showed to be effective after liver resection without complication, the debate on epidural analgesia continues. Coagulopathy, thrombocytopenia and other haematological abnormalities may impose additional risks of epidural hematoma formation following removal of the epidural catheter postoperatively. Especially there is a much greater incidence of co-existing liver cirrhosis in Chinese Hong Kong patients with hepatocelluar carcinoma. This group of patients is coagulopathic even before liver resection and the risk of bleeding complications related to epidural analgesia is a particular concern. Continuous wound instillation with local anesthetic agent by the ON-Q PainBuster System (I-Flow Corporation, Lake Forest, CA, USA) provides an attractive alternative for this group of patients. We had previously demonstrated its analgesic efficacy after open hepatic surgery in a randomized controlled trial. Recently, our group had reported, in a retrospective cohort, that successful implementation of ERAS protocol was associated with a significantly shorten hospital stay. However, there was no direct comparison with convention peri-operative program in a randomized controlled manner. Moreover, the peri-operative management in that study incorporated only a small proportion of components described in ERAS programs for liver surgery, namely pre-operative counselling, no premedication, normothermia during surgery, no nasogastric tube and no routine abdominal drain. Furthermore, patient-controlled morphine analgesia was the method for post-operative pain control, which might not be enough for open hepatectomy and might have restricted the mobilization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cancer
Keywords
Liver, Digestive system
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
94 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fast-track Arm
Arm Type
Experimental
Arm Description
Patients recruited will undergo ERAS perioperative program.
Arm Title
Conventional Group
Arm Type
No Intervention
Arm Description
Patients recruited to conventional group will undergo conventional perioperative program
Intervention Type
Other
Intervention Name(s)
Fast-track peri-operative program
Other Intervention Name(s)
Enhanced recovery after surgery(ERAS) peri-operative program
Intervention Description
Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.
All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia.
Primary Outcome Measure Information:
Title
Length of post-operative hospital Stay
Description
Post-operative hospital stay.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All consecutive patients undergoing elective liver resection (open and laparoscopic).
Age of patients between 18 and 70 years.
Patients with American Society of Anaesthesiologists (ASA) grading I-II.
Patients with no severe physical disability.
Patients who require no assistance on the activities of daily living.
Informed consent available will be recruited.
Exclusion Criteria:
Patients undergoing emergency surgery.
Patients who had received pre-operative portal vein embolization.
Patients who are expected to receive concomitant procedures other than cholecystectomy.
Pregnant ladies and patients who are mentally incapable of written consent will be excluded.
Patient who had previous history of Hepato-biliary and pancreatic surgery.
Patient who had chronic pain syndrome.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
CHING NING CHONG
Phone
2632 1496
Email
chongcn@surgery.cuhk.edu.hk
First Name & Middle Initial & Last Name or Official Title & Degree
CREC
Email
crec@cuhk.edu.hk
Facility Information:
Facility Name
Department of Surgery
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charing CHONG, MBChB
Phone
852 2632 1411
Email
chongcn@surgery.cuhk.edu.hk
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients
We'll reach out to this number within 24 hrs